Home›Caffeine

Caffeine

19 interactions on record

Caffeine has 19 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Dipyridamole, Warfarin, Warfarin Sodium. Patients taking Caffeine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 19
Major: 3
Moderate: 15

Major (3)

Caffeine + Dipyridamole— Caffeine may abolish the coronary vasodilation induced by intravenous dipyridamole, potentially leading to false negativ…
Caffeine + Warfarin— CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring
Caffeine + Warfarin Sodium— CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring.

Moderate (15)

Caffeine + Adenosine— Antagonizes the effects of adenosine, potentially reducing efficacy. Larger doses of adenosine may be required.
Caffeine + Ciprofloxacin— Systemic quinolones including ciprofloxacin interfere with the metabolism of caffeine.
Caffeine + Ciprofloxacin Hydrochloride— Systemic quinolones including ciprofloxacin interfere with the metabolism of caffeine.
Caffeine + Clozapine— Moderate or weak CYP1A2 inhibitor that may increase clozapine levels. Monitor patients closely and consider dose reducti…
Caffeine + Deferasirox— Deferasirox inhibits CYP1A2 resulting in increased caffeine concentration. Monitor for exposure related toxicity.
Caffeine + Enasidenib Mesylate— Enasidenib may increase the effect of caffeine in sensitive patients. Consider reducing caffeine intake from food and be…
Caffeine + Migalastat Hydrochloride— Co-administration decreases migalastat AUC and Cmax, which may reduce GALAFOLD efficacy. Avoid co-administration with ca…
Caffeine + Nicotine— Smoking cessation with nicotine replacement may require dose decrease due to deinduction of hepatic enzymes.
Caffeine + Ofloxacin— Systemic administration of quinolones interferes with the metabolism of caffeine.
Caffeine + Ofloxacin Ophthalmic Solution Usp, 0.3%— Systemic quinolone administration interferes with the metabolism of caffeine.
Caffeine + Regadenoson— Methylxanthine that interferes with the vasodilation activity of regadenoson. Patients should avoid consumption for at l…
Caffeine + Stiripentol— Stiripentol is an inhibitor and inducer of CYP1A2; consider dose adjustment of caffeine when administered concomitantly …
Caffeine + Terbinafine— Terbinafine decreases caffeine clearance by 19%.
Caffeine + Terbinafine Hydrochloride— Terbinafine decreases caffeine clearance by 19%, potentially increasing caffeine exposure.
Caffeine + Terbinafine Tablets 250 Mg— Terbinafine decreases the clearance of caffeine by 19%.

Caffeine + Dipyridamole⚠️Major

Caffeine may abolish the coronary vasodilation induced by intravenous dipyridamole, potentially leading to false negative thallium imaging results.

Caffeine + Warfarin⚠️Major

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring

Caffeine + Warfarin Sodium⚠️Major

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring.

Caffeine + Adenosine🟡Moderate

Antagonizes the effects of adenosine, potentially reducing efficacy. Larger doses of adenosine may be required.

Caffeine + Ciprofloxacin🟡Moderate

Systemic quinolones including ciprofloxacin interfere with the metabolism of caffeine.

Caffeine + Ciprofloxacin Hydrochloride🟡Moderate

Systemic quinolones including ciprofloxacin interfere with the metabolism of caffeine.

Caffeine + Clozapine🟡Moderate

Moderate or weak CYP1A2 inhibitor that may increase clozapine levels. Monitor patients closely and consider dose reduction if necessary.

Caffeine + Deferasirox🟡Moderate

Deferasirox inhibits CYP1A2 resulting in increased caffeine concentration. Monitor for exposure related toxicity.

Caffeine + Enasidenib Mesylate🟡Moderate

Enasidenib may increase the effect of caffeine in sensitive patients. Consider reducing caffeine intake from food and beverages during treatment.

Caffeine + Migalastat Hydrochloride🟡Moderate

Co-administration decreases migalastat AUC and Cmax, which may reduce GALAFOLD efficacy. Avoid co-administration with caffeine at least 2 hours before and 2 hours after taking GALAFOLD.

Caffeine + Nicotine🟡Moderate

Smoking cessation with nicotine replacement may require dose decrease due to deinduction of hepatic enzymes.

Caffeine + Ofloxacin🟡Moderate

Systemic administration of quinolones interferes with the metabolism of caffeine.

Caffeine + Ofloxacin Ophthalmic Solution Usp, 0.3%🟡Moderate

Systemic quinolone administration interferes with the metabolism of caffeine.

Caffeine + Regadenoson🟡Moderate

Methylxanthine that interferes with the vasodilation activity of regadenoson. Patients should avoid consumption for at least 12 hours before regadenoson administration.

Caffeine + Stiripentol🟡Moderate

Stiripentol is an inhibitor and inducer of CYP1A2; consider dose adjustment of caffeine when administered concomitantly with DIACOMIT.

Caffeine + Terbinafine🟡Moderate

Terbinafine decreases caffeine clearance by 19%.

Caffeine + Terbinafine Hydrochloride🟡Moderate

Terbinafine decreases caffeine clearance by 19%, potentially increasing caffeine exposure.

Caffeine + Terbinafine Tablets 250 Mg🟡Moderate

Terbinafine decreases the clearance of caffeine by 19%.

Caffeine + Tipranavirℹ️Unknown

Used as a probe substrate for CYP1A2 activity in phenotypic cocktail study with APTIVUS/ritonavir; no net effect at first dose but moderate induction at steady state.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.